KRAS and neoplasm: At difference with the transplantable K14-TSLPtg mouse model reported above (30), very recently DePinho and collaborators (59), using a transgenic mouse model of pancreatic cancer carrying an inducible oncogenic KRAS mutation, demonstrated a tumor-promoting function for Th2 cytokines from the tumor microenvironment, thus recapitulating the human disease.